Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer

Shiqi Li; Yi Zhu; Zhen Liang; Xiao Wang; Shuai Meng; Xin Xu; Xianglai Xu; Jian Wu; Alin Ji; Zhenghui Hu; Yiwei Lin; Hong Chen; Yeqing Mao; Wei Wang; Xiangyi Zheng; Ben Liu; Liping Xie

doi:10.18632/oncotarget.10575

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:684.

Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer

Shiqi Li, Yi Zhu, Zhen Liang, Xiao Wang, Shuai Meng, Xin Xu, Xianglai Xu, Jian Wu, Alin Ji, Zhenghui Hu, Yiwei Lin, Hong Chen, Yeqing Mao, Wei Wang, Xiangyi Zheng, Ben Liu and Liping Xie _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:51773-51783. https://doi.org/10.18632/oncotarget.10575

Metrics: PDF 2850 views | HTML 3144 views | ?

Abstract

Shiqi Li1,*, Yi Zhu1,*, Zhen Liang1, Xiao Wang1, Shuai Meng1, Xin Xu1, Xianglai Xu1, Jian Wu1, Alin Ji1, Zhenghui Hu1, Yiwei Lin1, Hong Chen1, Yeqing Mao1, Wei Wang1, Xiangyi Zheng1, Ben Liu1, Liping Xie1

1Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, PR China

*These authors contributed equally to this work and are Co-first authors

Correspondence to:

Ben Liu, email: [email protected]

Liping Xie, email: [email protected]

Keywords: bladder cancer, microRNA-877-3p, p16, RNA activation

Received: January 17, 2016 Accepted: June 29, 2016 Published: July 13, 2016

ABSTRACT

Despite the recent studies which have shown that microRNA (miRNA) negatively regulates gene expression by silencing the expression of target genes, here we reported the new evidence of microRNA-mediated gene activation by targeting specific promoter sites. We identified a miR-877-3p binding site on the promoter site of tumor suppressor gene p16 which alters frequently in bladder cancer. Enforced expression of miR-877-3p could increase the expression of p16, which inhibit the proliferation and tumorigenicity of bladder cancer through cell cycle G1-phase arrest. Further evidences confirmed that the correlation between p16 activation and miR-877-3p was due to the direct binding. These findings demonstrate the anti-tumor function of miR-877-3p in bladder cancer cells and reveal a new pattern of miRNA involved gene regulation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10575

Publication Alerts

Research Papers:

Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer

Abstract